Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Revance Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 13
Venture Financing 14
Revance Therapeutics Raises US$10 Million In Venture Financing 14
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 15
Revance Therapeutics Secures US$40 Million In Venture Financing 17
ReVance Therapeutics Secures US$5 Million In Financing Round 18
Equity Offering 19
Revance Therapeutics Plans to Raise up to USD75 Million in Public Offering of Shares 19
Revance Therapeutics Raises USD134.6 Public Offering of Shares 20
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 22
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 23
Revance Therapeutics Completes IPO For US$110.4 Million 25
Revance Therapeutics Inc – Key Competitors 27
Revance Therapeutics Inc – Key Employees 28
Revance Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 02, 2017: Revance Releases Third Quarter 2017 Results 30
Aug 03, 2017: Revance Releases Second Quarter 2017 Results 31
May 09, 2017: Revance Releases First Quarter 2017 Results 32
Feb 27, 2017: Revance Releases Fourth Quarter and Full Year 2016 Results 33
Nov 03, 2016: Revance Releases Third Quarter 2016 Results 35
Aug 04, 2016: Revance Releases Second Quarter 2016 Results 36
May 09, 2016: Revance Releases First Quarter 2016 Results 37
Mar 02, 2016: Revance Releases Fourth Quarter and Full Year 2015 Results 38
Corporate Communications 39
Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors 39
Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics 40
Jul 05, 2016: Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors 41
Product News 42
07/14/2016: Revance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines 42
01/12/2017: Revance Therapeutics Enters into $6.4M Settlement with City of Warren Police and Fire Retirement System 43
Clinical Trials 44
Jun 05, 2017: Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial 44
May 18, 2017: Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial 46
May 01, 2017: Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis 48
Mar 07, 2017: Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 49
Mar 03, 2017: Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting 50
Jan 26, 2017: BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 51
Jan 18, 2017: Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017 52
Jan 05, 2017: Revance Provides Clinical Milestones and Financial Outlook for 2017 53
Dec 12, 2016: Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial 54
Dec 07, 2016: Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 56
Nov 03, 2016: Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis 57
Jun 13, 2016: Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines 58
Mar 05, 2016: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology 59
Other Significant Developments 61
Jan 07, 2016: Revance Specifies 2016 Clinical Program Milestones 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Revance Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Revance Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 13
Revance Therapeutics Raises US$10 Million In Venture Financing 14
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 15
Revance Therapeutics Secures US$40 Million In Venture Financing 17
ReVance Therapeutics Secures US$5 Million In Financing Round 18
Revance Therapeutics Plans to Raise up to USD75 Million in Public Offering of Shares 19
Revance Therapeutics Raises USD134.6 Public Offering of Shares 20
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 22
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 23
Revance Therapeutics Completes IPO For US$110.4 Million 25
Revance Therapeutics Inc, Key Competitors 27
Revance Therapeutics Inc, Key Employees 28
Revance Therapeutics Inc, Subsidiaries 29